CorMedix Inc (NASDAQ: CRMD) has reported E.P.S. of $-0.05 for its third fiscal quarter (ending September 30) versus $-0.17 for the same period a year ago — a decline of -71%. E.P.S. were $-0.80 for the latest four quarters through September 30 versus $-0.85 for the same period a year ago — a decline of -6%.
Recent Price Action
CorMedix Inc (NASDAQ: CRMD) stock suffered a major decline of -22.5% on 10/30/24. The shares closed at $10.05. Moreover, exceptionally high trading volume at 379% of normal accompanied the decline. The stock has declined -16.5% during the last week but has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, CRMD is expected to continue to be Value Creation neutral.
CorMedix has a current Value Trend Rating of C (Neutral). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. CorMedix has a very low Appreciation Score of 2 but a very high Power Rating of 98, resulting in the Neutral Value Trend Rating.
Rating Review
In light of this new information and highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment